EUCTR2004-001159-12-IT进行中（未招募）不适用
A randomized phase II study of oxaliplatin and capecitabine combination vs irinotecan and capecitabine combination for the treatment of elderly patients with advanced colorectal cancer.
AZIENDA OSPEDALIERA S. CARLO0 个研究点开始时间: 2009年5月13日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Phase I/II study of the combination of Oxaliplatin and S-1 in patients with advanced/recurrent colorectal cancerunresectable advanced/recurrent colorectal cancerJPRN-C000000443Outpatient Oncology Unit Kyoto University Hospital42
已完成
3 期
A randomized phase III study of oxaliplatin based chemotherapy versus combination chemotherapy of TS-1,irinotecan and bevacizumab as first line therapy for unresectable or recurrent colorectal cancerJPRN-UMIN000007834The Tokyo Cooperative Oncology Group450
招募中
2 期
Phase II Study of Weekly Oxaliplatin With Continous Infusion Fluorouracil And Concurrent Radiation for Treatment of Localised Oesophageal CarcinomaHistologically confirmed localised squamous cell carcinoma of the oesophagusAdenocarcinoma of the oesophagusCancer - Oesophageal (gullet)ACTRN12605000106639Princess Alexandra Hospital30
已完成
不适用
A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)unresectable/advanced gastric cancerJPRN-UMIN000016256Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)12
已完成
不适用
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>ntreated metastatic gastric cancerJPRN-UMIN000022450The Tokyo Cooperative Oncology Group110